BRCA1 methylation and BRCA1 mutations in ovarian cancer.

摘要

With great interest we have read the much needed re-appraisal of BRCAl methylation studies in ovarian cancer [1]. The authors noted that differences in experimental methods resulted in a broad range of BRCAl methylation, between 5% and 40%. Indeed, Suijkerbuijk et al. [2] found a high discrepancy between methylation-spedfic PCR (MSP) and quantitative multiplex MSP (QM-MSP) in the same samples. However, two unrelated quantitative methods, QM-MSP and methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA), correlated strongly.